Platelets and People: Comparing Thrombocyte Patterns in African and Russian HIV Cohorts– A Review
DOI:
https://doi.org/10.67224/ioasdjmps.2026.v03i03.003Keywords:
HIV, thrombocytopenia, platelets, Africa, RussiaAbstract
Platelet abnormalities are common hematological manifestations of HIV infection, yet their patterns vary across regions due to differences in comorbidities, treatment access, and population-specific physiological baselines. Africa and Russia represent two distinct HIV epidemics with unique epidemiological drivers and hematologic reference norms. Understanding how platelet indices differ between these settings is essential for improving diagnostic accuracy and patient management. This review synthesizes evidence on thrombocyte patterns among HIV-positive cohorts in Africa and Russia, with emphasis on thrombocytopenia, regional baseline platelet reference ranges, and the influence of co-infections and treatment status. A narrative review was conducted through searches in PubMed, Scopus, Web of Science, and AJOL for studies published between 1990 and 2025. Observational and cohort studies reporting platelet indices in HIV-infected adults or children from African or Russian populations were included. Findings show that thrombocytopenia is more prevalent in African HIV cohorts, often driven by immune-mediated platelet destruction, opportunistic infections, and endemic co-infections such as malaria and tuberculosis. Russian cohorts exhibit platelet abnormalities more frequently linked to late HIV diagnosis, hepatitis C co-infection, and substance use–related complications. Regional platelet reference ranges differ considerably, with African populations generally showing lower baseline values than Russian or global standards, impacting diagnostic thresholds and disease classification. Platelet patterns in HIV infection vary markedly between Africa and Russia due to distinct epidemiologic and healthcare factors. Context-specific reference ranges and diagnostic criteria are essential for accurate monitoring and improved clinical decision-making.
References
1. Ayanyinka, A. D., Oyelayo, I., Okediji, A. S., Opaleye, O., Ojurongbe, O., & Olowe, O. A. (2025). Hepatitis B Virus (HBV), Human Im-munodeficiency Virus (HIV) and Tuberculosis (TB) infection: Challenges and global health strategies. Hosts and Viruses, 12, 70-82.
2. Yermukhanova, L., Kuzembayev, M., Salkhanova, A., Narymbayeva, N., Tazhiyeva, A., Makhanbetkulova, D. N., & Afshar, A. (2025). Exploring socio-economic dimensions in HIV research: a comprehensive bibliometric analysis (1992–2024). Global Health Action, 18(1), 2474787.
3. Madzime, M., Rossouw, T. M., Theron, A. J., Anderson, R., & Steel, H. C. (2021). Interactions of HIV and antiretroviral therapy with neutrophils and platelets. Frontiers in immunology, 12, 634386.
4. Shi, C., Li, X., Dai, Y., Chen, M., Mao, L., Zhou, X., ... & Yuan, W. (2025). Experiences, challenges, and needs of people living with HIV in Hunan Province, China: a qualitative study. Journal of Multidisciplinary Healthcare, 1405-1421.
5. Parczewski, M., Gökengin, D., Sullivan, A., de Amo, J., Cairns, G., Bivol, S., ... & Rockstroh, J. K. (2025). Control of HIV across the WHO European region: progress and remaining challenges. The Lancet Regional Health–Europe, 52.
6. Sanders, T. N., Roed, A. K. H., Missel, M., Berg, S. K., Nielsen, S. D., Olesen, M. L., & Kirk, O. (2025). Barriers to Retention in Care among Adults with HIV in Developed Countries: An Integrative Review. AIDS and Behavior, 29(7), 2205-2225.
7. Huang, M., Chen, C., Yu, B., Li, C., Zhang, Q., Jia, X., ... & He, Y. (2024). Thromboembolic disease in HIV/AIDS: More attention is needed. Chinese Medical Journal, 137(22), 2647-2650.
8. Saumoy, M., Fernandez, A., Tiraboschi, J., Peñafiel, J., Sánchez‐Quesada, J. L., Vega, J., ... & Imaz, A. (2025). Biomarkers of inflammation and coagulation predict non‐AIDS‐defining events in a prospective cohort of virologically suppressed people living with HIV. HIV medicine, 26(6), 849-857.
9. Obeagu, E. I., & Obeagu, G. U. (2024). Preventive measures against HIV among Uganda’s youth: Strategies, implementation, and effectiveness. Medicine, 103(44), e40317.
10. Opie J, Verburgh E, Bailly J, Mayne E, Louw V. (2024). Hematological Complications of Human Immunodeficiency Virus (HIV) Infection: An Update From an HIV-Endemic Setting. InOpen Forum Infectious Diseases; 11(4): ofae162).
11. Getawa, S., Aynalem, M., Bayleyegn, B., & Adane, T. (2021). The global prevalence of thrombocytopenia among HIV-infected adults: a systematic review and meta-analysis. International Journal of Infectious Diseases, 105, 495-504.
12. Marchionatti, A., & Parisi, M. M. (2021). Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. International Health, 13(2), 98-109.
13. Șoldea, S., Iovănescu, M., Berceanu, M., Mirea, O., Raicea, V., Beznă, M. C., ... & Donoiu, I. (2025). Cardiovascular disease in HIV patients: a comprehensive review of current knowledge and clinical implications. International Journal of Molecular Sciences, 26(5), 1837.
14. Abarca YA, Chadalavada B, Ceron JR, Sai BA, Bhatia A, Espinoza I, Rao NL, Khan R, Ansar R, Morani Z, Abarca-Pineda YA. (2025). A Comprehensive Review of the Manifestation of Cardiovascular Diseases in HIV Patients. Cureus.; 17(1).
15. Sönmez, I., Espelt, A., Majó, X., Bartroli, M., Meroño, M., González, V., ... & Folch, C. (2024). Trends in the prevalence of HIV, HCV, and co-infection and associated factors among young people who inject drugs (PWID) in Catalonia (2008–2019). Vulnerable Children and Youth Studies, 19(4), 661-675.
16. Stöver, H., Dichtl, A., Schäffer, D., & Grabski, M. (2023). HIV and HCV among drug users and people living in prisons in Germany 2022: WHO elimination targets as reflected in practice. Harm Reduction Journal, 20(1), 50.
17. Bisetegn, H., & Ebrahim, H. (2021). The prevalence of thrombocytopenia and leucopenia among people living with HIV/AIDS in Ethiopia: a systematic review and meta-analysis. PLoS One, 16(9), e0257630.
18. Alkholifi, F. K., Abdi, S. A. H., & Qadri, M. (2022). Global prevalence and associated clinical markers of thrombocytopenia in people living with HIV: evidence from meta-analysis. Clinics and Practice, 12(6), 867-875.
19. Sullivan, K. E., Bassiri, H., Bousfiha, A. A., Costa-Carvalho, B. T., Freeman, A. F., Hagin, D., ... & Tang, M. L. (2017). Emerging infections and pertinent infections related to travel for patients with primary immunodeficiencies. Journal of clinical immunology, 37(7), 650-692.
20. Obeagu, E. I. (2025). Cross-continental immunity: unraveling hematological markers of HIV in Africa and Russia-a perspective. Annals of Medicine and Surgery, 87(9), 5522-5527. doi: 10.1097/MS9.0000000000003617.
21. Prakash, P., Swami Vetha, B. S., Chakraborty, R., Wenegieme, T. Y., Masenga, S. K., Muthian, G., ... & Dash, C. (2024). HIV-associated hypertension: risks, mechanisms, and knowledge gaps. Circulation research, 134(11), e150-e175.
22. Louw, S., Jacobson, B. F., Wiggill, T. M., Chapanduka, Z., & Sarah Mayne, E. (2022). HIV‐associated thrombotic thrombocytopenic purpura (HIV‐TTP): A practical guide and review of the literature. HIV medicine, 23(10), 1033-1040.
23. Lv, X., Li, P., Yue, P., Tang, P., & Zhou, F. (2023). Risk factors and prognosis of thrombocytopenia in people living with HIV/AIDS. Therapeutic Advances in Hematology, 14, 20406207231170513.
24. Lazar, M., Moroti, R., Barbu, E. C., Chitu-Tisu, C. E., Tiliscan, C., Erculescu, T. M., ... & Olariu, M. C. (2024). The impact of HIV on early brain aging—A pathophysiological (re) view. Journal of Clinical Medicine, 13(23), 7031.
25. Bisetegn, H., & Ebrahim, H. (2021). The prevalence of thrombocytopenia and leucopenia among people living with HIV/AIDS in Ethiopia: a systematic review and meta-analysis. PLoS One, 16(9), e0257630.
26. Mozalyova, O. L., Samarina, A. V., & Rassokhin, V. V. (2022). Anemia and thrombocytopenia in HIV-positive pregnant women. Journal of obstetrics and women's diseases, 71(2), 69-78.
27. Alkholifi, F. K., Abdi, S. A. H., & Qadri, M. (2022). Global prevalence and associated clinical markers of thrombocytopenia in people living with HIV: evidence from meta-analysis. Clinics and Practice, 12(6), 867-875.
28. Talargia, F., & Getacher, L. (2021). Thrombocytopenia and associated factors among HIV infected patients in pre-and post-anti-retroviral therapy, North East Ethiopia. Journal of Blood Medicine, 741-748.
29. Tan, Y., Che, L., Bi, H., Fan, S., Zhou, Z., & Min, H. (2023). Clinical features and treatment effect of HIV-associated immune thrombocytopenia—single center Ten-Years data summary. Platelets, 34(1), 2200836.
30. Li, B., Zhang, L., Liu, Y., Xiao, J., Wang, X., Wei, Y., ... & Zhao, H. (2021). Manifestations and related risk factors of thrombocyte abnormalities in HIV-positive patients before and after the initiation of ART. Infection and Drug Resistance, 4809-4819.
31. Steel, H. C., Venter, W. F., Theron, A. J., Anderson, R., Feldman, C., Arulappan, N., & Rossouw, T. M. (2021). Differential responsiveness of the platelet biomarkers, systemic CD40 ligand, CD62P, and platelet-derived growth factor-BB, to virally-suppressive antiretroviral therapy. Frontiers in Immunology, 11, 594110.
32. Awamura, T., Nakasone, E. S., Gangcuangco, L. M., Subia, N. T., Bali, A. J., Chow, D. C., ... & Park, J. (2023). Platelet and HIV interactions and their contribution to non-AIDS comorbidities. Biomolecules, 13(11), 1608.
33. Rossouw, T. M., & Feldman, C. (2021). The role of platelet activation in the pathophysiology of HIV, tuberculosis and pneumococcal disease. Frontiers in Immunology, 12, 737016.
34. Pretorius, E. (2021). Platelets in HIV: a guardian of host defence or transient reservoir of the virus?. Frontiers in immunology, 12, 649465.
35. Louw, S., Gededzha, M. P., Mayne, A. L., & Mayne, E. S. (2022). Thrombotic thrombocytopenic purpura in HIV-infected patients: new twists on an old disease. AIDS, 36(10), 1345-1354.
36. Obeagu, E. I., & Obeagu, G. U. (2024). Protecting maternal health: strategies against HIV and malaria in pregnancy. Medicine, 103(36), e39565.
37. Zhang, Q., Sun, L., Liang, Y., Zou, W., Huang, J., Zhang, Y., ... & Chen, H. (2025). Patterns of liver fibrosis evolution in Chinese HIV/HBV co-infected adults following 5-year antiretroviral treatment: A longitudinal study using non-invasive APRI and Fib-4 scores. Virologica Sinica, 40(1), 118-124.
38. Pereira, L., Mutesa, L., Tindana, P., & Ramsay, M. (2021). African genetic diversity and adaptation inform a precision medicine agenda. Nature Reviews Genetics, 22(5), 284-306.
39. Plotkin, D., Titomer, A., Reshetnikov, M., Gafarov, U., Sterlikov, S., Sinitsyn, M., & Bogorodskaya, E. (2024). Frequency and risk factors of venous thromboembolic complications in patients with active pulmonary tuberculosis and HIV/TB co-infection (tuberculosis and thrombosis). Srpski arhiv za celokupno lekarstvo, 152(7-8), 357-362.
40. Raadsen, M., Du Toit, J., Langerak, T., van Bussel, B., van Gorp, E., & Goeijenbier, M. (2021). Thrombocytopenia in virus infections. Journal of Clinical Medicine, 10(4), 877.
41. Slukhanchuk, E. V., Bitsadze, V. O., Khizroeva, J. K., Solopova, A. G., Tsibizova, V. I., Yakubova, F., ... & Makatsariya, A. D. (2022). The role of platelets in antiviral immunity. Obstetrics, Gynecology and Reproduction, 16(2), 204-212.
42. Guseva, S. A., Goncharov, Y. P., Bilous, N. I., Tretiakov, V. V., & Savichan, K. V. (2024). Disseminated HIV-associated venous thrombosis (a case report). Ukrainian Journal of Military Medicine, 5(1), 148-155.
43. Alieva, A. M., Batov, M. A., Skripnichenko, E. A., Teplova, N. V., Baykova, I. E., Valiev, R. K., ... & Nikitin, I. G. (2023). Coronary heart disease in patients with human immunodeficiency virus infection. Russian Medicine, 29(1), 29-42.
44. Tan, Y., Che, L., Bi, H., Fan, S., Zhou, Z., & Min, H. (2023). Clinical features and treatment effect of HIV-associated immune thrombocytopenia—single center Ten-Years data summary. Platelets, 34(1), 2200836.
45. Kholodnaia, A., So-Armah, K., Cheng, D., Gnatienko, N., Patts, G., Samet, J. H., ... & Lioznov, D. (2022). Impact of illicit opioid use on markers of monocyte activation and systemic inflammation in people living with HIV. Plos one, 17(5), e0265504.
46. Li, B., Zhang, L., Liu, Y., Xiao, J., Wang, X., Wei, Y., ... & Zhao, H. (2021). Manifestations and related risk factors of thrombocyte abnormalities in HIV-positive patients before and after the initiation of ART. Infection and Drug Resistance, 4809-4819.
47. Mandania EW. (2024). Haematological and Immunological Abnormalities in People Living With HIV: A Review. Journal of Medical and Biomedical Laboratory Sciences Research. 4(1).
48. Nkoa, T., Moundanga, M., Bangola, D. M., Fokam, J., & Mangala, C. (2021). Residual risk of HIV in African transfusional setting: Systematic review and meta-analysis. International STD Research & Reviews, 10(2), 25-36.
49. Giguère, K., Eaton, J. W., Marsh, K., Johnson, L. F., Johnson, C. C., Ehui, E., ... & Maheu-Giroux, M. (2021). Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data. The Lancet HIV, 8(5), e284-e293.
50. Zuma, K., Simbayi, L., Zungu, N., Moyo, S., Marinda, E., Jooste, S., ... & Sabssm V Study Group Contributors. (2022). The HIV epidemic in South Africa: key findings from 2017 national population-based survey. International journal of environmental research and public health, 19(13), 8125.
51. Nascimento, F. G., & Tanaka, P. Y. (2012). Thrombocytopenia in HIV-infected patients. Indian Journal of Hematology and Blood Transfusion, 28(2), 109-111. doi: 10.1007/s12288-011-0124-9.
52. Johnson, L. F., Meyer-Rath, G., Dorrington, R. E., Puren, A., Seathlodi, T., Zuma, K., & Feizzadeh, A. (2022). The effect of HIV programs in South Africa on national HIV incidence trends, 2000–2019. JAIDS Journal of Acquired Immune Deficiency Syndromes, 90(2), 115-123.
53. Ogarkova, D., Antonova, A., Kuznetsova, A., Adgamov, R., Pochtovyi, A., Kleimenov, D., ... & Mazus, A. (2023). Current trends of HIV infection in the Russian Federation. Viruses, 15(11), 2156.
54. Ozhmegova, E., Lebedev, A., Antonova, A., Kuznetsova, A., Kazennova, E., Kim, K., ... & Bobkova, M. (2024). Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia. HIV medicine, 25(7), 862-872.
55. Kashnitsky, D., & Richter, J. M. (2022). ‘In Short, We Will Deport You’: Disrupted temporalities of migrants with HIV in Russia. Global Public Health, 17(11), 2841-2853.
56. Omosigho, P. O., Ilesanmi, A. O., Olaleke, N. O., & Okesanya, O. J. (2023). Thrombocytopenia in HIV positive patients in Ilorin North-Central Local Government Area Kwara State, Nigeria. Journal of Global Health Science, 5(2).
57. Vyawahare, C., Mukhida, S., Khan, S., Gandham, N. R., Kannuri, S., & Bhaumik, S. (2024). Assessment of risk factors associated with drug-resistant tuberculosis in pulmonary tuberculosis patients. Indian Journal of Tuberculosis, 71, S44-S51. doi: 10.1016/j.ijtb.2023.07.007.
58. Kamvuma, K., Hamooya, B. M., Munsaka, S., Masenga, S. K., & Kirabo, A. (2024). Mechanisms and cardiorenal complications of chronic anemia in people with HIV. Viruses, 16(4), 542.
59. Schapkaitz E, Jacobson BF, Libhaber E. (2023). Pregnancy related venous thromboembolism-associated with HIV infection and antiretroviral therapy. InSeminars in Thrombosis and Hemostasis; 49 (04): 355-363.
60. Justice, A. C., Goetz, M. B., Stewart, C. N., Hogan, B. C., Humes, E., Luz, P. M., ... & Althoff, K. N. (2022). Delayed presentation of HIV among older individuals: a growing problem. The Lancet HIV, 9(4), e269-e280.
61. World Health Organization. (2022). WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. World Health Organization.
62. Ngwa, A. F., Nsongmayi, E. D., Bobga, T. P., Tita, B. V., Nyeme, J. N., & Mbuh, N. E. (2024). Malaria parasitemia and its association with CD4 cells, viral load and haematological parameters among HIV-infected children< 15 years in the Bonasssama Health District, Douala, Cameroon: Prevalence and risk factors. Parasite Epidemiology and Control, 27, e00390.
63. Horberg, M., Thompson, M., Agwu, A., Colasanti, J., Haddad, M., Jain, M., ... & Tookes, H. (2024). Primary care guidance for providers who care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, ciae479.
64. Obeagu, E. I., Obeagu, G. U., Ukibe, N. R., & Oyebadejo, S. A. (2024). Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine, 103(2), e36937.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Emmanuel Ifeanyi Obeagu, Olga Goryavheva Goryavheva, Mikhail Anatolyevich Zubarev (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The IOASD Journal of Medical and Pharmaceutical Sciences publishes all articles under the Creative Commons Attribution–NonCommercial 4.0 International (CC BY-NC 4.0) License. Under this license, readers are free to copy, distribute, share, adapt, and reproduce the published work in any medium or format for non-commercial purposes, provided that appropriate credit is given to the original author(s) and the source.
